Q2 2025 Earnings Call Transcript August 18, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.63 EPS, ...

Nyxoah gains FDA approval for its Genio system, signaling a major growth milestone. Explore revenue growth, risks, and why ...

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Reports Q2 revenue EUR 1.34M vs. EUR 771,000 last year. “This FDA approval represents a historic milestone for Nyxoah (NYXH) and marks the ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Analysts estimate that Nyxoah will report an earnings per share (EPS) of $-0.63. Nyxoah bulls will hope to hear the company ...

Nyxoah SA (NASDAQ:NYXH) is set to release its Q2 2025 earnings on Aug 18, 2025. The consensus estimate for Q2 2025 revenue is ...

Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate presentation on Monday, March 17, 2025, at 8:40am ET. A webcast of the presentation will be available in the Events ...